Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Daniel den Hoed Cancer Center, Rotterdam, Netherlands

Survival: 18.4 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Netherlands
City/State/Province: Rotterdam
Hospital: Daniel den Hoed Cancer Center
Journal: Link
Date: 11/2012

This study involved metastatic castration-resistant prostate cancer patients with metastases to the bone who were divided into two separate treatment groups. There were 301 patients in group A with a median age of 69 years. Group B had 291 patients with a median age of 68 years.

Patients in group A were treated with the chemotherapy agent docetaxel.
Patients in group B were treated with docetaxel and the drug risedronate, which inhibits bone resorption (degradation).

There were two treatment-related deaths due to infection in group A. Grade 3-4 diarrhea and neurotoxicity were also reported.

The most severe toxicities were of grade 4 and included grade 3-4 neutropenia and neurotoxicity.

The median overall survival for groups A and B was 18.4 and 19.2 months, respectively.

This study was supported by Sanofi-Aventis, makers of risedronate.

Correspondence: Dr. H.J. Meulenbeld; email:

E-mail to a Friend Email Physician More Information